S&P 500   5,096.27
DOW   38,996.39
QQQ   439.00
Pure Storage, Hormel Foods rise; WW International, First Advantage fall, Thursday, 2/29/2024
Critical asset just had biggest fall on record (Ad)
How major US stock indexes fared Thursday, 2/29/2024
Average long-term US mortgage rises to 6.94% after marking fourth-straight weekly increase
Critical asset just had biggest fall on record (Ad)
Best Buy reports lower 4Q sales and profits as shoppers remain cautious
Grads From This Midwestern School Are More Likely to Start a Billion Dollar Company Than Founders Who Went To Stanford, Harvard, or MIT: Study
Critical asset just had biggest fall on record (Ad)
It's Leap Day, and You're Probably Working — Here's How 'February 29' Affects Your Paycheck
From Hometown Hero to Franchise Partner — 3 Celebrities Collaborating With Their Hometown Brands
S&P 500   5,096.27
DOW   38,996.39
QQQ   439.00
Pure Storage, Hormel Foods rise; WW International, First Advantage fall, Thursday, 2/29/2024
Critical asset just had biggest fall on record (Ad)
How major US stock indexes fared Thursday, 2/29/2024
Average long-term US mortgage rises to 6.94% after marking fourth-straight weekly increase
Critical asset just had biggest fall on record (Ad)
Best Buy reports lower 4Q sales and profits as shoppers remain cautious
Grads From This Midwestern School Are More Likely to Start a Billion Dollar Company Than Founders Who Went To Stanford, Harvard, or MIT: Study
Critical asset just had biggest fall on record (Ad)
It's Leap Day, and You're Probably Working — Here's How 'February 29' Affects Your Paycheck
From Hometown Hero to Franchise Partner — 3 Celebrities Collaborating With Their Hometown Brands
S&P 500   5,096.27
DOW   38,996.39
QQQ   439.00
Pure Storage, Hormel Foods rise; WW International, First Advantage fall, Thursday, 2/29/2024
Critical asset just had biggest fall on record (Ad)
How major US stock indexes fared Thursday, 2/29/2024
Average long-term US mortgage rises to 6.94% after marking fourth-straight weekly increase
Critical asset just had biggest fall on record (Ad)
Best Buy reports lower 4Q sales and profits as shoppers remain cautious
Grads From This Midwestern School Are More Likely to Start a Billion Dollar Company Than Founders Who Went To Stanford, Harvard, or MIT: Study
Critical asset just had biggest fall on record (Ad)
It's Leap Day, and You're Probably Working — Here's How 'February 29' Affects Your Paycheck
From Hometown Hero to Franchise Partner — 3 Celebrities Collaborating With Their Hometown Brands
S&P 500   5,096.27
DOW   38,996.39
QQQ   439.00
Pure Storage, Hormel Foods rise; WW International, First Advantage fall, Thursday, 2/29/2024
Critical asset just had biggest fall on record (Ad)
How major US stock indexes fared Thursday, 2/29/2024
Average long-term US mortgage rises to 6.94% after marking fourth-straight weekly increase
Critical asset just had biggest fall on record (Ad)
Best Buy reports lower 4Q sales and profits as shoppers remain cautious
Grads From This Midwestern School Are More Likely to Start a Billion Dollar Company Than Founders Who Went To Stanford, Harvard, or MIT: Study
Critical asset just had biggest fall on record (Ad)
It's Leap Day, and You're Probably Working — Here's How 'February 29' Affects Your Paycheck
From Hometown Hero to Franchise Partner — 3 Celebrities Collaborating With Their Hometown Brands
NASDAQ:RGNX

REGENXBIO (RGNX) Stock Price, News & Analysis

$17.44
-2.46 (-12.36%)
(As of 02/29/2024 ET)
Today's Range
$17.12
$20.48
50-Day Range
$12.17
$20.02
52-Week Range
$11.83
$25.32
Volume
1.08 million shs
Average Volume
769,462 shs
Market Capitalization
$774.86 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$35.13

REGENXBIO MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.63 Rating Score
Upside/​Downside
101.4% Upside
$35.13 Price Target
Short Interest
Bearish
10.58% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.82
Upright™ Environmental Score
News Sentiment
0.04mentions of REGENXBIO in the last 14 days
Based on 18 Articles This Week
Insider Trading
Selling Shares
$2.12 M Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($2.83) to ($3.05) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.94 out of 5 stars

Medical Sector

243rd out of 958 stocks

Biological Products, Except Diagnostic Industry

31st out of 152 stocks


RGNX stock logo

About REGENXBIO Stock (NASDAQ:RGNX)

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy. In addition, it also develops RGX-121 for the treatment of mucopolysaccharidosis type II and is in Phase III clinical trial; RGX-111, which is in Phase I/II clinical trial for treating mucopolysaccharidosis type I; RGX-181 for the treatment of late infantile neuronal ceroid lipofuscinosis type II; and RGX-381 to treat the ocular manifestations of CLN2 disease. Further, the company also licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies; and has a collaboration and license agreement with Neurimmune AG to develop novel gene therapies. REGENXBIO Inc. was founded in 2008 and is headquartered in Rockville, Maryland.

RGNX Stock Price History

RGNX Stock News Headlines

REGENXBIO (NASDAQ:RGNX) Rating Reiterated by Wedbush
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
REGENXBIO (NASDAQ:RGNX) Shares Gap Down Following Weak Earnings
Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
Regenxbio Q4 2023 Earnings Preview
REGENXBIO (RGNX) Scheduled to Post Quarterly Earnings on Tuesday
RGNX Mar 2024 20.000 call
See More Headlines
Receive RGNX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for REGENXBIO and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/27/2024
Today
3/01/2024
Next Earnings (Estimated)
5/01/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:RGNX
Fax
N/A
Employees
401
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$35.13
High Stock Price Target
$55.00
Low Stock Price Target
$20.00
Potential Upside/Downside
+101.4%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.63
Research Coverage
8 Analysts

Profitability

Net Income
$-280,320,000.00
Net Margins
-291.99%
Pretax Margin
-292.15%

Debt

Sales & Book Value

Annual Sales
$90.24 million
Book Value
$7.02 per share

Miscellaneous

Free Float
38,405,000
Market Cap
$774.86 million
Optionable
Optionable
Beta
1.20
Beginner's Guide to Pot Stock Investing Cover

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Key Executives

  • Mr. Kenneth T. MillsMr. Kenneth T. Mills (Age 49)
    President, CEO & Director
    Comp: $1.02M
  • Mr. Vittal K. Vasista (Age 56)
    Executive VP & CFO
    Comp: $671.41k
  • Mr. Curran M. Simpson M.S. (Age 62)
    Executive VP & COO
    Comp: $677.7k
  • Dr. Olivier Danos Ph.D. (Age 66)
    Executive VP & Chief Scientific Officer
    Comp: $728.06k
  • Dr. Stephen Pakola M.D. (Age 55)
    Executive VP & Chief Medical Officer
    Comp: $673.76k
  • Mr. Patrick J. Christmas II (Age 53)
    J.D., Executive VP & Chief Legal Officer
    Comp: $1.11M
  • Ms. Shiva G. Fritsch
    Chief Communications & People Officer
  • Dr. Laura A. Coruzzi J.D. (Age 70)
    Ph.D., Executive Vice President of Intellectual Property
  • Dr. Ram Palanki Pharm.D. (Age 48)
    Executive VP of Commercial Strategy & Operations
  • Dr. Stephen Yoo M.D. (Age 46)
    Consultant
    Comp: $573.71k














RGNX Stock Analysis - Frequently Asked Questions

Should I buy or sell REGENXBIO stock right now?

8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for REGENXBIO in the last twelve months. There are currently 3 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" RGNX shares.
View RGNX analyst ratings
or view top-rated stocks.

What is REGENXBIO's stock price target for 2024?

8 equities research analysts have issued 12 month target prices for REGENXBIO's stock. Their RGNX share price targets range from $20.00 to $55.00. On average, they predict the company's share price to reach $35.13 in the next twelve months. This suggests a possible upside of 101.4% from the stock's current price.
View analysts price targets for RGNX
or view top-rated stocks among Wall Street analysts.

How have RGNX shares performed in 2024?

REGENXBIO's stock was trading at $17.95 at the beginning of the year. Since then, RGNX shares have decreased by 2.8% and is now trading at $17.44.
View the best growth stocks for 2024 here
.

When is REGENXBIO's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 1st 2024.
View our RGNX earnings forecast
.

How were REGENXBIO's earnings last quarter?

REGENXBIO Inc. (NASDAQ:RGNX) announced its earnings results on Tuesday, February, 27th. The biotechnology company reported ($1.43) EPS for the quarter, missing the consensus estimate of ($1.27) by $0.16. The biotechnology company had revenue of $22.30 million for the quarter, compared to the consensus estimate of $34.01 million. REGENXBIO had a negative net margin of 291.99% and a negative trailing twelve-month return on equity of 64.05%. The company's quarterly revenue was down 28.8% on a year-over-year basis. During the same period in the prior year, the business earned ($1.38) earnings per share.

What ETFs hold REGENXBIO's stock?

ETFs with the largest weight of REGENXBIO (NASDAQ:RGNX) stock in their portfolio include Global X Genomics & Biotechnology ETF (GNOM).Virtus LifeSci Biotech Clinical Trials ETF (BBC).

What is Ken Mills' approval rating as REGENXBIO's CEO?

3 employees have rated REGENXBIO Chief Executive Officer Ken Mills on Glassdoor.com. Ken Mills has an approval rating of 68% among the company's employees.

What other stocks do shareholders of REGENXBIO own?

Based on aggregate information from My MarketBeat watchlists, some companies that other REGENXBIO investors own include AbbVie (ABBV), Micron Technology (MU), NVIDIA (NVDA), Voyager Therapeutics (VYGR), Amarin (AMRN), CRISPR Therapeutics (CRSP), Pfizer (PFE), QUALCOMM (QCOM), Gilead Sciences (GILD) and Block (SQ).

Who are REGENXBIO's major shareholders?

REGENXBIO's stock is owned by many different institutional and retail investors. Top institutional investors include Vanguard Group Inc. (10.10%), Dimensional Fund Advisors LP (2.79%), Northern Trust Corp (1.02%), Sonic GP LLC (1.01%), Perceptive Advisors LLC (0.78%) and Goldman Sachs Group Inc. (0.76%). Insiders that own company stock include Allan M Fox, Kenneth T Mills, Kenneth T Mills, Steve Pakola, Vittal Vasista and WR Stephens, Iii 2012 Trust.
View institutional ownership trends
.

How do I buy shares of REGENXBIO?

Shares of RGNX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:RGNX) was last updated on 3/1/2024 by MarketBeat.com Staff